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This narrative review summarizes a selection of recent, clinically-important novel gastrointestinal de-
velopments, presented and discussed at the European Gastro Update In Budapest. The selected topics 
reflect what the distinguished faculty considered of vital importance to be communicated to the astute 
busy gastro-hep clinician, who is eager to stay well informed of important novel developments in his 
discipline. Whenever appropriate a personal comment or addition was added to further raise the edu-
cational value of this review. Given its narrative character, statements and conclusions are largely expert 
opinion-based and referencing is limited to the selected images.
Novel upper gastrointestinal developments 
Prof Peter Malfertheiner
Gastro-esophageal reflux disease (GERD) may well be furt-
her increasing as H. Pylori infection risk continues to fall. 
Pathophysiological concepts, summarized in the figure 
below remain essentially unchanged (Fig. 1) but there is 
increasing interest in the concomitant role of functional 
dyspepsia with mucosal gastro-duodenal inflammation, 
delayed gastric emptying and impaired gastric accommo-
dation, all favoring transient sphincter relaxations, toget-
her with enhanced sensitivity.
Hypersensitivity appears, in part, related to altered af-
ferent signaling and aberrant sensory characteristics. 
Whereas infusion of menthol in the esophagus evoked a 
mild cold sensation in healthy subjects, this was percei-
ved as rather painful heartburn in GERD patients. Refrac-
toriness to proton pump inhibition (PPI) (esomeprazole 
40mg/d/8w) remains a challenging problem and deserves 
prolonged multichannel impedance-pH investigation. As 
shown in an Italian study, only one third of such patients 
had non-erosive reflux disease (+acid exposure time and 
+symptom association probability), the others suffered 
from reflux hypersensitivity (normal acid exposure time) 
or from functional heartburn. For those true non-respon-
ders, more profound acid suppression with a potassium-
competitive acid blocker (pCAB) would be an option. As 
shown in the figures below, the mechanism of action of 
pCABs differs from that of PPIs (Fig. 2, Fig. 3). A recent Ja-
panese study in PPI-refractory patients showed normali-
sation of esophageal acid exposure in 46%, together with 
symptom improvement and healing of esophagitis with 
20 mg/d vonoprazan. For the time being pCABs are not 
(yet) available in Europe.
Regurgitation, particularly when severe, may also be ref-
ractory even to high-dose PPI therapy and calls for other 
approaches, such as endoscopic fundoplication, magnetic 
sphincter augmentation, or standard antireflux surgery.
Esophageal columnar metaplasia (Barrett) continues to 
raise major clinical interest and controversy. Whether all 
patients with Barrett esophagus, also those that are asy-
mptomatic should enter a surveillance program to detect 
early neoplasia, is not answered in a uniform way in the 
currently existing guidelines. It is also somewhat cont-
roversial whether acid suppression with PPIs decreases 
the cancer risk because PPIs are commonly prescribed 
for reduction of heartburn symptoms. In support of non-
stop acid suppression was a recent nested case-control 
study in 300 American veterans showing a 41% reduc-
tion in esophageal adenocarcinoma in PPI users. Can 
chemoprevention be further improved by combining 
PPIs with aspirin? The long-awaited results of the large 
British AspECT chemoprevention study, which randomi-
zed 2,557 patients to low-(20 mg/d) or high-dose (40 mg 
× 2/d) esomeprazole with or without 300 mg aspirin/d, 
followed for a median 8.9 years, were recently published. 
High-dose PPI was superior to low-dose PPI in delaying 
the combined end point of [all-cause mortality, high-gra-
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de dysplasia or adenocarcinoma]. Aspirin was not signifi-
cantly associated with a decreased risk of the combined 
outcome. It would appear that the benefit of the study 
was largely related to a reduction of all-cause mortality. 
What does this all mean for clinicians? For the time being 
clinicians should try to stratify patients in a low or high 
risk category using the common clinical/endoscopic cha-
Figure 2. P-CABs (vonoprazan, revaprazan) 
and PPIs Main Differences in the Mechanism 
of Action (2)
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Figure 1. Pathophysiology of gastroesophageal reflucx disease (1)
racteristics. Low risk patients should be advised to stop 
smoking, moderate the diet and receive chemopreven-
tion with (high dose) PPI and aspirin. High risk patients 
should enter an endoscopic surveillance program and 
be treated whenever dysplastic/neoplastic changes de-
velop with endoscopic resection and/or radiofrequency 
ablation or other alternative modalities. Remember that 
it is not unusual that only about half of the clinicians ad-
here to established guidelines.
Inappropriate polypharmacy, especially in older people, 
imposes a substantial burden of adverse drug events, ill 
health, disability, hospitalization and even death. It was 
estimated that 30% of American elderly consumed 5–9 
pills per day. PPIs, of which the consumption is still rising, 
were often included. When correctly prescribed PPIs play 
an essential therapeutic role in medicine. A recent high-
quality systematic review and meta-analysis demonstra-
ted the substantial benefits of PPI treatment. Over 140,000 
patients were analysed in 580 prevention trials, 233 hea-
ling trials and 36 bleeding trials. Compared to controls and 
other gastro-protectants, PPIs were overall 5 times more 
effective in reducing risk and 5 times more effective in tis-
sue improvement/healing. This glamorous result needs to 
be balanced with the negative consequences of long-term 
PPI induced acid suppression, particularly when related to 
enhanced esophageal and gastric cancer risk as discussed 
in last year’s highlight. Despite all critical comments and 
study shortcomings, it would seem sensible to add neop-
lasia to well-known list of adverse events, shown in the fi-
gure below (Fig. 4).
The enhanced gastric cancer risk of long-term acid supp-
ression may well be related in part to gastric dysbiosis 
and perhaps to chronically elevated gastrin levels. Inte-
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restingly, in one study the enhanced risk was only seen in 
those individuals who were not taking additional Aspirin. 
Clinicians should be aware of the above-mentioned as-
sociation studies, while realising that randomized cont-
rolled trials are impossible and that association studies 
are always prone to known and unknown confounders. 
Anyhow, the main message of all these studies is that ch-
ronic profound (PPI-induced) acid suppressant therapy 
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Figure 3. Time course of acid inhibition by P-CABs and PPIs: computer 
simulation (3)
Hunt RH, Scarpignato C. Curr Treat Options Gastroenterol 2018 Dec; 16(4): 570–590.
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Figure 4. PPI and adverse events Ongoing 
debates (4)
should only be prescribed 
for the proper indications, 
realising that a very subs-
tantial percentage of PPI 
prescriptions, also in the 
elderly, are inappropriate.
Eosinophilic esophagi-
tis prevalence is rising 
also in the Far East, beco-
ming the leading cause of 
esophageal food impacti-
on in children and young 
adults. The prevalence, 
calculated in 24 studies is 
now ~34/100.000. Note 
that a proper diagnosis 
does no longer require 
disease resistance to PPI 
therapy, as up to 60% 
of genuine eosinophilic 
esophagitis patients res-
pond to PPIs, presumably 
based at least in part upon 
their anti-inflammatory 
activity. The terminology of PPI-responsive esophageal 
eosinophilia should therefore be omitted in clinical prac-
tice. The updated international consensus diagnostic cri-
teria for eosinophilic esophagitis includes: – symptoms of 
esophageal dysfunction – at least 15 eosinophils per high-
power field (~60/mm2) and – comprehensive exclusion of 
other disorders that could contribute to esophageal eo-
sinophilia. The most important pathogenetic features are 
summarized in the figure below (Fig. 5).
According to a systematic review, H. Pylori exposure was 
associated with a 37% reduction in the risk of eosinophi-
lic esophagitis. This finding fits with the observation 
that exposure to H. Pylori early in life skews immune res-
ponsiveness more in the T helper 1 direction than in the 
pro-allergy T helper 2 direction. Medical therapy usually 
starts with PPIs, followed by corticosteroids if PPIs fail. 
A recent 8 week controlled trial comparing oral viscous 
budesonide with fluticasone inhalation revealed equal 
reduction in mucosal eosinophilia and improvement in 
dysphagia. Two important drivers of eosinophilic activa-
tion are IL-5 and IL-13. A monoclonal antibody targeting 
IL-5 has already been shown to be efficacious. Novel is 
the experimental evaluation of a monoclonal antibody 
against IL-13 which was also shown to be efficacious in 
reducing esophageal eosinophilia and in reducing sy-
mptomatology, deserving further evaluation. Not dis-
cussed at the meeting but important to mention is the 
renewed interest in empiric elimination diet to decrea-
se the allergenic load. It all started with the step-down 
six-food elimination diet, followed by 4-food and the 
2-food elimination diet (the 6-4-2 system) with the gra-
dual re-introduction of nutrients, a costly time-consu-
ming laborious procedure. A more rational, patient-fri-
endlier approach, decreasing the endoscopic burden, 
was launched in Spain, the (2-4-6) step-up protocol, thus 
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starting with the 2-food (milk, 
wheat) elimination diet (which 
was effective in ~40%, the majori-
ty related to avoidance of milk or 
dairy) with sequential elimination 
of other food items. Ultimately, 
there will be a sequence of elimi-
nations: (dairy), (+wheat), (+egg), 
(+soy/legumes), (+nuts, seafood), 
(+beef/corn). In practice, succes-
sful dietary therapy demands 
substantial patient education, 
engagement and motivation to 
adhere to the elimination diet.
It is common knowledge that H. 
Pylori infection is associated with 
multiple gastroduodenal and 
extra-intestinal manifestations. In 
a recent important meta-analysis 
the role of H. Pylori infection was 
evaluated in low-dose Aspirin us-
ers. In infected individuals, the 
risk of Aspirin-induced ulceration 
rose by almost 70% and in the ab-
sence of protective acid suppressants, by almost 100%. 
Low-dose Aspririn, variably defined in the literature is 
not innocent therapy. I wonder to what extent chronic 
low-dose Aspirin may be related to the common anemia 
seen in the elderly.
Most of the information of H. Pylori eradication in the pre-
vention of gastric cancer was generated in the Far East. 
Now, also data from a western population became avai-
lable. A population based cohort of over 95,000 individu-
als with eradication of the infection was followed; overall 
0.1% developed gastric cancer. The risk decreased gra-
dually with incidence ratios of 8.6 after 3-5 y and 0.3 after 
5-7.5 y of follow-up, confirming the gradual suppression 
of gastric cancer development. Similar results were seen 
in asymptomatic individuals from a health screening 
program; compared to controls the risk of gastric cancer 
expressed as hazard ratio’s (HR) was 4.12 and dropped to 
2.73 in those after H. Pylori eradication. One may readily 
assume that such cancer protective effect is related to 
the gradual improvement of atrophic gastritis and even 
(partial) reversibility of intestinal metaplasia after era-
dication of the infection. Such phenomenon may also 
explain the prevention of metachronous gastric cancer 
shown in a randomized trial of 470 patients after endos-
copic removal of early gastric cancer. Metachronous can-
cer developed in 7% in the eradiation group versus 13% 
in the placebo group, again paralleled by improvement 
in atrophy in respectively 48% versus 15%. Despite some 
recent publications from the western world, it is still unc-
lear whether population screening for H. Pylori infection 
and serologic screening for pre-neoplastic gastric mu-
cosal atrophy/metaplasia is warranted. Should serologic 
screening be encouraged in combination with screening 
for colorectal neoplasia in individuals above 59 y in wes-
tern societies that have low or intermediate risk of gastric 
Figure 5. Pathogenesis of eosinophilic esophagitis (5)
O'Shea KM, Aceves SS, Dellon ES, et al. Gastroenterology 2018 Jan; 154(2): 333–345.
cancer? Should fecal occult blood screening be combi-
ned with stool H.Pylori antigen screening?
The drama with the rising antimicrobial resistance, parti-
cularly for clarithromycin, metronidazole and levofloxacin 
continues. Successful therapies for infectious diseases 
should ideally be susceptibility-based but this involves 
extra costs and effort compared to empiric therapies. This 
dilemma was recently studied in a controlled trial invol-
ving 382 patients, randomized to 14 d empiric quadruple 
therapy (esomeprazole, bismuth, amoxicillin, metroni-
dazole) versus susceptibility-guided therapy, with res-
pective eradication rates per protocol of 97.6% versus 
97.7% and per intention-to-treat of 85.4% versus 91.6, a 
non-significant difference. It remains difficult to recom-
mend susceptibility-based treatment for first-line therapy 
in clinical practice until such therapy is proven to be su-
perior and cost-effective. Perhaps all this will change if the 
initial remarkable eradication results with 14 d dual thera-
py with high-dose esomeprazole and amoxicillin can be 
reproduced in other cohorts in the west. The results mirror 
the high eradication also obtained with dual therapy with 
the pCAB vonoprazan and amoxicillin. It would certainly 
be progress if such dual therapy would be effective beca-
use resistance to amoxicillin is almost negligable; the only 
problem would be penicillin allergy.
Small bowel diseases and infections 
Prof Gerhard Rogler
Celiac disease is thought to affect 1% of the western popu-
lation. HLA haplotypes DQ2 and DQ8 are present in over 
90% of the celiac patients compared to ~40% in the gene-
ral population. Celiac disease may be associated with ot-
her autoimmune diseases. In addition to intestinal symp-
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Figure 6. Current strategies for non-dietary treatment of celiac disease (6)
SerenaG, et al. Gastroenterol Clin North Am. 2019 Mar; 48(1): 145–163.
toms, celiac disease may be complicated by vitamin and 
trace mineral deficiencies, bone disease and malignancy. 
Non-celiac gluten intolerance/sensitivity and seronegative 
celiac disease have recently been described. Perhaps ente-
rovirus infection may increase the risk of developing celiac 
disease. Monthly stool samples from Norwegian DQ2/DQ8 
positive children were checked starting from age month 3 
to 36 for enterovirus and adenovirus using RT-PCR. After a 
mean of ~10 y, celiac disease was diagnosed in 25 of 220 
children. Enterovirus was found in 17% of the stool samp-
les and was significantly more frequent in samples collec-
ted before development of celiac disease antibodies. Such 
data are quite intriguing and ask for more information to 
fully understand the way early viral infection leads to celi-
ac enteropathy in predisposed individuals.
A meticulously followed gluten-free diet is so far the only 
treatment to antagonize the chronic inflammatory tissue 
destruction. An important recent study revealed that chro-
nic inflammation permanently reconfigures the tissue-resi-
dent lymphocytic compartment. Normally there is a stable 
tissue-resident lymphocyte population which plays a key 
role in immune surveillance. In celiac disease, gluten-in-
duced inflammation triggers a depletion of such naturally 
occurring intraepithelial lymphocytes. Exclusion of dietary 
gluten appears insufficient to reconstitute this important 
subset of intraepithelial lymphocytes. Clinicians should 
be aware of the extensive differential diagnosis in celiac-
like mucosal abnormalities; conditions accompanied by 
enhanced intraepithelial lymphocytosis include: NSAID 
or PPI consumption, Giardia or Cryptosporidium infecti-
on, immunodeficiency disorders, bacterial overgrowth, 
IBS etc.; conditions accompanied by villus atrophy with or 
without intraepithelial lymphocytosis include: angioten-
sin receptor blocker-associated enteropathy (olmesartan 
etc.), mycophenolate mofetil, autoimmune enteropathy, 
immunodeficiency disorders, eosinophilic disorders, che-
moradiation etc. Olmesartan-associated enteropathy is an 
under-diagnosed cause of diarrhea, weight loss and pan-
malabsorption. Lifelong strict gluten-free diet therapy is 
demanding, which explains the many strategies for non-
dietary treatment which are currently being explored as 
exemplified in the figure below (Fig. 6)
Hopefully some results of the many ongoing trials will lead 
to clinically useful application in the future. The American 
Gastroenterology Association recently published a clinical 
practice update on diagnosis and monitoring of celiac di-
sease. What follows is a selection of the recommendations. 
High tissue transglutaminase (tTG-IgA) levels are reliable 
for diagnosing active disease. When celiac disease is sus-
pected but biopsies are negative, positive tTG-IgA should 
lead to repeat biopsy sometime in the future. When pati-
ents have already started a gluten-free diet before a pro-
per diagnosis was made, it is suggested that the patient 
goes back to a normal diet with three slices of wheat bread 
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daily for 1-3 months before repeat determination of tTG-
IgA. A biopsy-avoiding diagnostic pathway was schemati-
cally suggested as shown in the figure below (Fig. 7).
There is a rising interest for ‘point of care’ testing for seve-
ral diseases, also for celiac disease with Simtomax, which 
detects IgA and IgG antibodies against deamidated glia-
din peptides. This test was prospectively evaluated in over 
1,000 German patients, of whom 4.1% had celiac disease. 
Simtomax’s sensitivity and specificity were respectively 
79% and 94%, and positive and negative predictive value 
37% and 99%, therefore unsuitable as a screening test in 
routineclinical practice.
Non-celiac gluten sensitivity, detected by controlled glu-
ten challenge, may be present in a minority of all those 
avoiding gluten containing food (the gluten hype). Avoi-
ding wheat products in such patients not only lowers the 
gluten intake but also the amount of FODMAPs, which 
may contribute to the symptom improvement. Yet a mild 
gluten-triggered immune reaction may also be ongoing in 
those sensitive individuals as suggested by higher num-
bers of intraepithelial CD3+ T-cells and lamina propria 
CD45+ cells and eosinophils in duodenal mucosa. More 
detailed studies are necessary before we understand the 
pathophysiological differences between celiac disease 
and gluten/wheat sensitivity.
Campylobacter jejuni is the leading cause of foodborne 
bacterial enteritis in humans. As shown in a large German 
study, consumption of chicken meat (74%) and eating out 
were the most important factors for campylobacter infec-
tion. Problematic is the rising antimicrobial resistance. In 
Japan, the ciprofloxacin resistance rose in ~10 y from 35% 
to 42%. Also in a Turkish cohort, campylobacter isolates 
were found to be resistant to ciprofloxacin (74%), tetracy-
clin (25%) and erythromycin (6%). In a French cohort, qui-
nolone resistance rose from 48% to 55%. These are alar-
ming figures making erythromycin or azithromycin now 
the treatment of choice. Prevention is crucial and only 
possible by meticulous avoiding of food contamination via 
raw chicken meat during food preparation.
Also non-typhoidal salmonella bacteremia is increasing 
especially in the elderly, as shown in a recent British study. 
Note that 34% of the bacteremia isolates were resistant to 
a first-line antibiotic regimen, frequently quinolone. Death 
occurred in 12% of the (most often) elderly patients. Other 
studies also pointed to the steady rise of plasmid-media-
ted quinolone resistance in human non-typhoidal salmo-
nella infections.
The frequency of clostridioides difficile (a gram-positive, 
spore-forming anaerobic bacterium) is increasing worldwi-
de. The infection may lead to severe life-threatening (pseu-
domembranous) colitis. The most important risk factors 
include antibiotic therapy, old age and hospital stay. Diagno-
sis is based on toxin detection in stool. Toxin A is an enteroto-
xin damaging the mucosal barrier function and stimulating 
intestinal secretion, and toxin B is a cytotoxin-driving inflam-
mation. Antibiotic therapy of choice is based on vancomycin, 
fidaxomicin and, less so, metronidazole. In severe or recurrent 
or refractory patients, fecal microbiota transplantation may 
be successful in >90%. In successfully treated patients, a rapid 
and sustained stool enrichment was seen with microorgan-
isms producing a bile salt hydrolase. This hydrolase converts 
taurocholic acid, a potent trigger for C. difficile germination, 
to cholic acid and deoxycholic acid, potent inhibitors of C. dif-
ficile growth. New British Society of Gastroenterology guide-
lines include the following statements:
• sterile 0.9% saline should be considered as an approp-
riate diluent for fecal transplant production and cryopro-
tectant, such as glycerol should be added for frozen pre-
parations;
•  >50 g stool, should be used per transplant preparation 
– stool should be mixed 1:5 with diluent to make the 
emulsion;
•  homogenisation and filtration of the preparation should 
be undertaken in a closed disposable system.
Figure 7. AGA Clinical Practice Update on Diagnosis and Monitoring of Celiac Disease (7)
Symptomatic group
Husby et al. Dastroenterology 2019; 156: 885–889.
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More than 30 million individuals worldwide are yearly 
affected by traveller’s diarrhea. For prophylaxis, bismuth 
subsalicylate may be considered for any traveler, and rifaxi-
min (but not fluoroquinolones) when antibiotic prophyla-
xis is indicated. The illustration below summerizes recent 
overall recommendations for traveller’s diarrhea (Fig. 8).
For moderate disease, both azithromycin (preferably a 
single dose) and rifaximin may be considered.Rifamy-
sin SV-MMX is a novel poorby absorbed broad spectrum 
antibiotic, active against an-/aerobic,gram-pos/neg pat-
hogens and shown to be as effective as ciprofloxacin, 
without substantial induction of extended-spectrum be-
ta-lactamase-producing Escherichia coli.
Novel large bowel developments 
Prof Jaroslaw Regula
Colorectal cancer is increasing worldwide, also in Europe 
where incidence and mortality were analysed from 1990 
to 2016 in over 140 million people (20 countries) of whom 
over 180,000 had colorectal cancer diagnosed. The cancer 
incidence increased for the age group (20–29 y) by almost 
8% (30–39 y) by almost 5% and (40–49 y) by 1.6%. The 
young-onset colorectal cancer was mainly due to rectal 
cancer in white individuals. Such puzzling rise in young-
onset colorectal cancer could also be seen in population-
based registries from several high-income countries, sho-
wing a decreasing incidence in people aged 50–74 y, but 
an increasing incidence in the 20–49 y old group. One can 
only speculate what the reasons could be for this distres-
sing phenomenon: obesity causing smoldering inflamma-
tion? Microbiome changes due to antibiotic use? Inappro-
priate western-style diet? Food contaminants? Radiation 
exposure? More frequent predisposing genetic abnorma-
lities? Other reasons? The question was even raised in the 
literature, whether the more frequent early-age onset sho-
uld require lowering the starting age for screening, but so 
far relevant guidelines remained unchanged.
Many studies have shown the colorectal cancer preven-
tive activity of acetylsalicylic acid. Whether another an-
ti-platelet agent, clopidogrel, was also cancer preventive 
was analysed in a large Spanish nested case-control study, 
involving over 15,000 colorectal cancers and 60,000 ran-
domly matched controls. When drug use was longer than 
one y, the adjusted Odds Ratio for acetylsalicylic acid was 
0.79 and for clopidogrel 0.65. Why clopidogrel may dec-
rease the incidence of colorectal cancer is unknown. The 
well-known and generally accepted prophylactic activity 
of acetylsalicylic acid was seriously questioned by the 
shocking results of a recent American study, involving clo-
}Figure 8. ????? (8)Providers should consider the following information in counseling the traveler during pre-travel counseling:(1) Definitions of travelers' diarrhea and severity classification(2) Importance of oral rehydration through fluid and salt intake for all travelers' diarrhea(3)  Information on effectiveness of treatments for travelers' diarrhea and the risk of travel, travelers' diarrhea and antibiotic use with the acquisition of multi-drug resistance bacteria(4)  Provision of antibiotics, loperamide, bismuth subsalicylates as indicated per itinerary and provider-traveler determination(5) Intra=and post-travel illness follow-up recommendationsMild Moderate SevereDiarrhea that is tolerabe, is  not distressing and does not interfere with planned activities Diarrhea that distressing or interferes with planned activities Diarrhea that is incapaciating or comple-tely prevents planned activitiesNon-dysentery DysenteryMay use loperamide or bismuth  subsalicylates to control stooling May use loperamide alone or as an adjunct to antibiotics May use loperam-ide as an adjunct to antibioticsMay use antibiotic therapy (Table X) Should use antibiotic therapy (Table X)
Acute travelers' diarrhea should be treated empirically as above
Microbiologic testing is recommended in returning travelers with severe or persistent symptoms or in those who fail empiric therapy
Multiplex molecular diagnostic are preferred in patients with persistent or chronic symptoms
Riddle MS et al. J Travel Med. 2017 Apr 1; 24 (Suppl:1): S57–S74.
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se to 20,000 people above 70 y, comparing a low dose of 
100 mg/d versus placebo for the duration of ~4.7 y. In the 
acetylsalicylic acid group the hazard ratio’s for
•  all-cause mortality was (1.14);
•  overall cancer related death (1.31);
•  and colorectal cancer-related death (1.77).
Why the drug was not helpful in preventing colorectal 
cancer in the elderly and why it even shortened overall 
survival was unexpected, puzzling and shocking, and begs 
for confirmation and explanation!
Whether a healthy lifestyle is useful in colorectal cancer 
prevention was studied in over 40,000 patients compared 
to over 3,000 controls. The healthy lifestyle score was deri-
ved from five modifiable lifestyle factors: smoking, alcohol 
consumption, diet, physical activity, and body fatness. The 
genetic risk score was based on 53 known risk variants, 
based on genome-wide association studies. The higher 
the lifestyle score, the lower the cancer risk, independent-
ly of the genetic risk score. It is not known whether the 
mentioned lifestyle factors are of equal importance but 
regular physical activity seems important as also shown 
by other studies. Also diet is important as shown in the 
nurses/ health professionals follow-up study involving 
over 120,000 participants. Based on questionnaires the 
consumed diet pattern was classified as pro-inflammatory 
or as anti-inflammatory. Interestingly, the pro-inflamma-
tory diet increased the risk of Fusobacterium nucleatum 
positive colorectal cancers. Presumably the pro-inflamma-
tory diet altered the intestinal microbiome, favoring the 
outgrow of F. nucleatum, shown also in other studies to be 
commonly associated with colorectal cancer.
A novel quality metric to measure the impact of organised 
screening for colorectal cancer was recently proposed. The 
method is based upon the determination of the proporti-
on of colorectal cancers, detected either by:
•  screening;
•  non-adherence (due to non-existing or non-adherence 
to existing screening programs);
•  or interval cancers (screening done but cancer arose be-
fore the next recommended control).
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An example of this metric may be seen in a recent American 
study. Of 572 cancers, 34.4% were screen detected 59.4% 
non-adherent and 6.1% interval cancer. Such metric data can 
now be compared between centers to evaluate and compare 
the screening efficacy. Obviously, the percentage screen-de-
tected should be as high as possible and the percentage of 
interval cancers as low as possible. In real life it turns out to 
be quite difficult to lower the interval percentage, explaining 
the ongoing search for methods to improve the neoplasia de-
tection rate during endoscopy. As pan-chromo-endoscopy is 
not very appealing for many colonoscopists, a variant was 
developed adding methylene blue MMX to the polyethylene 
glycol bowel prep solution, leading to more uniform colonic 
staining. Adding 200 mg methylene blue MMX versus place-
bo was evaluated in a multicenter controlled trial involving 
over 1,200 patients. The overall results are summerized in the 
figure below (Fig. 9).
Methylene blue MMX added to the bowel prep significant-
ly increased the adenoma detection rate. Whether this 
method will become the standard for screening requires 
further study.
Chronic use of acetylsalicylic acid or anticoagulants (war-
farin or DOACs) is common in screening. Whether they in-
terfere with Fecal immunochemical testing (FIT) for occult 
blood loss is somewhat controversial in the literature. To 
find out if FIT testing is reliable in users of those drugs, the 
positive predictive value was evaluated in 4,908 Norwegian 
individuals, including 1,008 acetylsalicylic acid users, 147 
warfarin users and 212 DOAC users. The positive predictive 
value both for cancer and for advanced adenoma was sig-
nificantly lower in the acetylsalicylic acid and DOAC users. 
Both patients and providers need to take note of this in-
formation when analysing the FIT results. The mechanisms 
explaining the phenomenon remain to be explored.
Not covered at the meeting but worthwhile mentioning 
are several recent data stressing the importance of addi-
tional ablation of the resection margins after colorectal 
polyp resection or the inclusion of an extra few mm of 
normal mucosa when cold resection is used to decrease 
the neoplasia recurrence rate, which may range up to 30% 
after removal of large flat lesions.
Symptomatic uncomplicated diverticular disease (SUDD) 
is a new disease entity, the pathophysiology of which is 
poorly understood. Indeed some 20% of patients with co-
lonic diverticulosis develop symptoms without obvious 
signs of inflammation. To differentiate SUDD from IBS may 
be challenging. Using biopsies from the diverticular area 
compared to distant sites, immunochemical investigations 
revealed accumulation of macrophages in the peridiverti-
cular mucosa. Nerve fiber sprouting was increased only in 
the diverticular region in SUDD patients, suggesting a role 
in symptom generation. The cause of these subtle mucosal 
alterations remains enigmatic but currently there is high 
research interest for mucosal interaction with the microbi-
ome. In the same line is the interest in the efficacy of long-
term rifaximin treatment (800 mg/d/7 d every month) for 
8 y, as studied in 346 Italian SUDD patients compared to 
470 similar patients, treated on demand by other means. 
There was significant improvement with rifaximin in the 
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score for pain and bloating and stool frequency. These are 
intriguing results, begging for confirmation and for clarifi-
cation of the underlying mechanism.
Novel pancreatic developments
Prof Peter Layer
The steadily rising incidence over the previous decades of 
acute and chronic pancreatitis, presumably related to al-
cohol and tabacco consumption, obesity and cholelithia-
sis, was recently shown in a large American insurance data 
base to decline in adults, but not in children, as shown in 
the figures below (Fig. 10, Fig. 11). If this decline is related 
to decreasing nicotine consumption or increasing endos-
copic/surgical obesity treatment remains speculative.
Eluxadoline, a mixed opi oid receptor modulator, availab-
le in some European countries for diarrhea-predominant 
irritable bowel syndrome, was shown in a post-marke-
ting surveillance, to be 
responsible for inducing 
acute pancreatitis in over 
16% of the adverse events 
compared to less than 1 % 
for all other anti-diarrheals 
(related to sphicter of Oddi 
dysfunction?). This would 
demand a re-evaluation of 
eluxadoline’s benefit-ha-
zard ratio.
Ramadan, celebrated by 
Muslims, includes dawn-
to-dusk fasting, followed 
by an opulent evening 
meal which may lead 
to massive gall bladder 
contractions, perhaps 
favoring gall stone mo-
bilization with risk of 
pancreatitis. Indeed the 
risk of acute pancreati-
tis was shown to be 2.5 
times higher during the 
Ramadan month. Follo-
wing prolonged fasting, 
massive nutritive stimula-
tion may lead to vigorous 
contraction of a disten-
ded gall bladder, to rapid 
increase in serum trigly-
cerides and glucose and 
to massive stimulation of 
pancreatic enzyme secre-
tion. Ramadan followers 
should be advised to bre-
ak the fast gradually, es-
pecially if cholelithiasis is 
present.
A simple cheap and par-
ticularly rapid prognostic 
marker in acute pancreatitis is the neutrophil-to-lympho-
cyte ratio in peripheral blood. The normal ratio is ~1.65. 
A value >10 was shown to predict high severity of acute 
hypertriglyceridemia-induced pancreatitis, with prolon-
ged hospital stay, enhanced risk for SIRS and renal failure. 
These exciting data warrant further prospective evaluati-
on in all forms of acute pancreatitis.
Acute pancreatitis is often associated with nausea, vomi-
ting, gastrointestinal hypomotility and subileus, conditi-
ons favoring bacterial overgrowth, bacterial translocation 
and infectious complications. Bacterial overgrowth, studi-
ed by a (poorly sensitive) glucose breath test at day 7 in 
over 200 pancreatitis patients, was demonstrable in over 
25% of the patients with a severe cause and with organ 
complications. Early enteral feeding, whenever feasible, 
would presumably lead to early stimulation of gastrointes-
tinal motility and reduction of intestinal stagnation and 
bacterial overgrowth.
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Healing of acute pancreatitis may be associated with irre-
versible structural and functional deficits. The prevalence 
of exocrine pancreatic insufficiency was evaluated some 
36 m after the acute attack in a meta-analysis involving 
almost 1,500 patients. Exocrine insufficiency was present 
in one quarter of the patients, particularly in patients with 
alcoholic pancreatitis or with a severe necrotizing course. 
Clinicians should be on the outlook for insufficiency du-
ring follow-up. Unfortunately an easy simple (stool) test, 
also sensitive for minor degrees of insufficiency, is still not 
available.
Over the last few years, a paradigm shift has occurred with 
respect to the management of acute necrotising pancrea-
titis. Early emergency surgery (often open necrosectomy) 
is obsolete and initial management should be conservati-
ve. If surgical intervention should be necessary it should 
be selective, late-elective and leading to minimal trauma. 
Minimally invasive surgery led to a 20–30% lower morta-
lity compared to open necrosectomy. Also endotherapy 
in high risk patients had a 60–79% lower mortality com-
pared to open necrosectomy. Optimal management of 
severe acute pancreatitis with infected necrosis requires 
an individually adapted minimally invasive strategy. If in-
terventions are needed, endoscopic methods are less tra-
umatic and produce overall better results compared with 
minimally invasive surgery. This was again confirmed in a 
recent study, showing that endoscopic therapy when per-
formed in experienced centers by experts is safe and cost-
effective. The main reasons for endoscopic superiority was 
a lesser occurrence of enteral or pancreatic-cutaneous 
fistulae and lower rate of systemic inflammatory response 
syndrome.
Chronic pancreatitis is a dreadful condition. Alcohol and 
smoking has a deleterious influence on the natural evo-
lution as shown by a ~10 y follow-up study comparing al-
coholics (75% smokers) to non-alcoholics (<40% smokers). 
Chronic pain, pseudocysts, pancreatitis flares, exocrine 
insufficiency, and number of hospitalisations were signifi-
cantly higher in the alcoholic cohort. Stressing the need to 
abstain from alcohol and to stop smoking remains of high 
clinical relevance. Intriguing is the impact of statins on the 
natural evolution of chronic pancreatitis, as shown in a po-
pulation based cohort of close to 5,000 patients of whom 
43% died and 2.4% developed pancreatic cancer. Overall 
mortality, disease progression and pancreatic cancer risk 
were lower in statin users. Statin use may be associated 
with protective (anti-fibrogenetic, anti-carcinogenetic) 
effects in chronic inflammatory diseases such as chronic 
pancreattis.
Intraductal papillary mucinous neoplasia (IPMN) may 
occasionally lead to cancer, particularly when invol-
ving the main pancreatic duct. Many use the Fukuoka 
criteria to estimate the cancer risk, looking for – wor-
risome features (WF) (pancreatitis, cyst >3 cm, thicke-
ned or enhanced cystic wall, main pancreatic duct >5 
mm, non-enhanced cyst mural nodule, abrupt change 
in main pancreatic duct caliber with distal atrophy) 
and high-risk stigmata (HR) (obstructive jaundice, solid 
components with enhancement, main pancreatic duct 
>10 mm). European guidelines were recently published 
regarding the diagnostic and therapeutic management 
of IPMN as shown below (Fig. 12).
Based on several new studies following main recommen-
dations conclusions can be drawn:
•  IPMNs, even if initially Fukuoka negative, are (and be-
come) never “safe”. Therefore, long-term surveillance ( >5 
y ) is warranted, as long as the patient is fit for surgery;
•  initial cyst size alone is not a worrisome feature per se 
but predicts later development of worrisome features, as 
does also occur for rapidly enlarging cysts by >2.5 mm/y.
Figure 12. Diagnostic and Therapeutic Management of IPMM: European Guidelines (12)
Opetable
Gut 2018; 67: 789–804.
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For cysts of an indeterminate nature, measuring glucose 
in the cyst fluid may offer a simple, quick, cheap and pre-
cise diagnostic marker for its neoplastic nature. This was 
shown in a study of over 150 resected cystic lesions of va-
rious subtypes. Cyst glucose was substantially lower in the 
mucinous type cysts compared to non-mucinous cysts. 
Using a glucose cut-off value of 50 mg/dl, the accuracy of 
the glucose test was 90% compared to 69% for CEA deter-
mination with a cut-off at 192 ng/ml.
Cyst ablation may be attempted in high risk IPMN in pati-
ents unfit for pancreatic surgery by EUS-guided instillation 
of cytostatic drugs (gemcitabine and paclitaxel) dissolved 
in alcohol or saline respectively. Complete cyst ablation at 
12 m was obtained in respectively 61% and 67%, with se-
vere 30 d adverse events in 6% versus 0% and mild 30 d 
adverse events in 22% versus 0%. These results need to be 
confirmed in other studies with long-term follow-up befo-
re this method becomes standard therapy.
Pancreatic cancer remains the number one dismal co-
nundrum in gastroenterology. For many years, prevention 
has been suggested by drugs such as acetylsalicylic acid 
and vitamin D. Disappointingly the large long-term Ameri-
can nurses/ health professionals study revealed that both 
drugs offered no relevant protection against pancreatic 
cancer. As biomarkers for early disease are not yet avai-
lable, we are left to be on the outlook for early symptoms. 
Newly diagnosed diabetes may be the first symptom of an 
underlying pancreatic malignancy. This was nicely shown 
in 219 cancer cases versus 440 controls. As shown in the 
figure below (Fig. 13), hyperglycemia may be observed as 
early as 30 – 36 m prior to cancer diagnosis. The degree 
of blood glucose elevation correlated with both the tumor 
size and degree of undifferentiation.
Development of pancreatic cancer points to complex in-
teractions with the metabolism of glucose, with chronic 
hyperglycemia favoring neoplasia. Therefore, in all pati-
ents with new-onset of diabetes, particularly when asso-
ciated with preceding weight loss, increased vigilance is 
mandatory and, as a rule, abdominal ultrasound is war-
ranted.
Novel developments in intestinal 
endoscopy
Prof Oliver Pech
Most western studies on endoscopic resection of early 
esophageal malignancy are related to adenocarcinoma. 
Now a new French multicenter study with long-term 
follow-up of endoscopic resection of 148 squamous cell 
cancers was presented, 54% treated with mucosal resec-
tion and 46 % treated with submucosal dissection. Medi-
an lesion size was 20.5 mm; 38% were piece-meal resec-
ted; depth of cancerous infiltration was (m 1-2) in 64% 
and (m3-sm) in 36%; the procedure was complicated by 
bleeding in 2%, perforation in 2% and led to stricturing 
in 14%. During a median follow-up of 22 months, tumor 
recurrence was observed in 14.2%. Significant risk factors 
for recurrence, expressed as hazard ratios were: –removal 
by mucosal resection (17) – pT1m3-sm (3) – need for ad-
ditional chemoradiotherapy (7) – non-curative resection 
(12). If at all possible piece-meal resection should be avo-
ided and for larger lesions or suspicion for submucosal 
ingrowth, submucosal dissection is to be preferred. Ra-
diofrequency ablation of early sqamous cancer has also 
been evaluated in 35 Chinese patients. Complete respon-
se was seen in 86%. Tumor recurrences were observed 
in 20% but could all be treated with endoscopic resecti-
on. Meticulous examination of the resection specimens 
suggested that initial expansion of cancerous growth in 
the ductular epithelial lining of the submucosal glands, 
extending deeper than the muscularis mucosae and 
therefore not ablated, was the presumed cause of the 
cancerous recurrence.
Although it is commonly known that longstanding acha-
lasia is a risk factor for squamous cancer, little is known 
about the impact of 3 yearly endoscopic screening with 
lugol staining as evaluated in a cohort of 230 patients 
followed for a median of 56 m after various treatments 
(pneumodilation, surgical myotomy, POEM,PPI etc.) Sta-
sis of food or liquids was observed in 27% during 1 or 
more endoscopies. In ~a quarter of the endoscopies 
reflux esophagitis, usually grade A and B, was detected. 
Low grade dysplasia was detected in 3% and evolved 
into cancer in 1.3%, resulting in an overall incidence 
rate of sqamous cancer of 63/100,000 person-years. The 
incidence rate of low grade dysplasia started rising af-
ter 20 y of achalasia symptoms and cancer after 30 y of 
symptoms. Stagnant decomposing food and fluid and 
bacterial overgrowth, leading to chronic mucosal injury 
and inflammation, are considered to contribute to the 
oncogenic process and should be the leading target of 
the various therapies.
Studies continue to be published regarding the therapy 
with resection and/or usually radiofrequency ablation of 
neoplastic columnar metaplastic (Barrett) mucosa, con-
firming studies mentioned in previous highlights. Cont-
roversies remain whether patients should be intensively 
surveilled in the absence of any dysplasia or whether asy-
mptomatic patients should be treated with non-stop PPI 
antisecretory treatment. Whether there are prognostic 
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phenotypes for esophageal adenocarcinoma was pros-
pectively evaluated in a separate American and British 
cohort. Interestingly the overall survival in both cohorts 
was substantially better when intestinal metaplasia was 
present in the peritumoral mucosa compared to those 
where intestinal metaplasia was absent. Thus adenocar-
cinoma without intestinal metaplasia appeared to have a 
significantly worse outcome. A confounder in the concept 
of two different types of esophageal adenocarcinoma is 
the fact that it is almost impossible to rule out overgrowth 
of intestinal metaplasia by aggressive tumor expansion. 
All this reminds the ongoing controversy regarding the 
requirement of intestinal metaplasia with goblet cells as a 
prerequisite for proper diagnosis of Barrett type columnar 
metaplasia.
Usually covered self-expanding metal stents are used for 
palliation of advanced esophageal carcinoma, largely to 
prevent cancerous ingrowth. The full covering however fa-
vors the risk of migration. Does it help to leave both ends 
of the stent uncovered? In a controlled Dutch trial, almost 
100 patients were randomized to fully versus partially co-
vered stents. No differences were found between the 2 
stent types regarding technical success and frequency of 
recurrent obstruction. Recurrent obstruction was more 
frequent for proximal cancers.
Benign strictures usually respond to bougie/balloon di-
lation therapy but some are truly recalcitrant and recur-
rent. Is temporary stenting with a biodegradable stent 
with chronic dilation while tissue remodeling occurs hel-
pful in such patients with recurrent benign esophageal 
strictures? In a controlled multicenter trial, 66 patients 
with esophageal strictures, most often anastomotic 
strictures, with prior dilation up to at least 16 mm were 
randomized. During the first 3 months significantly less 
repeat endoscopic dilations were necessary in the biode-
gradable stent grou, but significance was no longer seen 
at 6 months. The median time to the first re-dilation was 
longer in the stent group (106 d) versus the control group 
(42 d). There were 2 perforations in the control group ver-
sus 5 stent occlusions, 2 tracheoesophageal fistulas and 
1 migration in the stent group. I am wondering what the 
proper indications (if any) are for biodegradable stenting 
and if radial incision with a needle-knife would not be a 
more attractive approach for anastomotic stricturing, re-
alising however that no controlled comparative studies 
are available.
Bleeding in the upper gastrointestinal tract remains a 
challenge, particularly for recurrent bleeding of peptic 
ulcers. To find out whether over-the-scope (OTSC) clips 
are superior to standard therapy with clipping or coa-
gulation, 66 patients were randomized in a multicenter 
study. Persistent bleeding or recurrent bleeding within 
7 d was significantly lower in the OTSC group (15%) ver-
sus the control group (58%). Ulcer type, Forrest type, 
Rockall score, anticoagulation and type of prior endos-
copic therapy had no significant impact. OTSC clipping 
requires adequate anatomic targeting of the bleeding 
area which may occasionally be challenging; perhaps 
monopolar hemostatic forceps may be helpful in such 
circumstances. A consecutive cohort of 112 Turkish pa-
tients with bleeding gastroduodenal ulcers were rando-
mized to treatment with monopalar hemostatic forceps 
with soft coagulation versus hemoclipping. Hemostasis 
was obtained in respectively 98% versus 80% with a me-
dian of 3 clips. Monopolar hemostatic forceps was suc-
cessful in all clip failures (persistent or recurrent bleeding 
within 7 d). Hemostatic forceps were more effective than 
hemoclips independent from ulcer and bleeding type. 
Other studies have confirmed the usefulness of hemosta-
tic forceps in the treatment of acute bleeding.
Peroral endoscopic myotomy (POEM) has become the mi-
nimally invasive treatment of choice for achalasia in many 
centers. A well-documented adverse consequence is the 
high frequency and often severe nature of reflux disease, 
sometimes insufficiently controlled with acid suppressant 
therapy. Surgical Heller-type myotomy is often combined 
with partial (Dor-type) fundoplication. Is a comparable 
combination possible by endoscopic means? This was at-
tempted in a rather provocative proof of concept study 
by Inoue, the inventor of POEM. Distal to the myotomy, 
the proximal stomach was perforated, allowing endosco-
pic entry into the peritoneal cavity, positioning of a lar-
ge endoloop over de fundus, anchoring the most distal 
and proximal part of the loop with clips and final closing 
the loop creating a partial fundoplication. There were no 
complications and the plication appeared endoscopically 
detectable in almost all patients 2 m later. Obviously many 
questions remain to be answered but such attempt is a 
nice illustration of the ongoing exploration of novel thera-
peutic possibilities.
Using the submucosal tunnel space to approach the 
muscle layer is not limited to the esophageal sphincter. A 
logical extension was to cut the obstructing gastric pyloric 
sphincter complex, called G-POEM to ameliorate refrac-
tory gastroparesis. A meta-analysis of 7 studies, involving 
almost 200 such patients was presented. Clinical success 
was seen in 82% and the gastroparesis cardinal symptom 
index decreased significantly in parallel, with scintigraphic 
emptying studies. Obviously large controlled trials are 
required now to identify the subset of patients where this 
novel therapy would be most appropriate, also with long-
term follow-up.
All endoscopists are aware of the difficulties in getting 
permanent optimal cleaning/desinfection of the endosco-
pic equipment. What is insufficiently realised is the risk of 
bacterial exposure of the face of the endoscopist during 
the procedure through exposure to blood and body flu-
ids. Swabs of plastic face shields worn by the endosopist 
or positioned on the suite wall were cultured before and 
after the procedure. The number of bacterial colony for-
ming units was low before the endoscopy but rose subs-
tantially post-procedure in 46% of the face shields worn 
by the endoscopists and in 21% hanging on the suite wall. 
Unrecognized face exposure occurs 5.6 times per 100 half-
day endoscopic procedures and individuals standing up to 
6 feet away from the patient may still be exposed at a rate 
of 3.4 per 100 half-day presence in the endoscopy suite. 
The authors of that study make a plea for routine face pro-
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tection for the endoscopist and assisting staff. Uncleaned 
suite surfaces may aid in patient-to-patient transmission 
of pathogens.
A major drawback of endoscopic (mucosal) resection 
of usually large laterally spreading colonic adenomas is 
the high recurrence rate of up to 30%, especially after 
piece-meal resection, as discovered during surveillance 
after 3–6 m. Can thermal ablation of the resection mar-
gin reduce this high recurrence rate? This was investiga-
ted in a large multicenter controlled trial in Australia in 
laterally spreading lesions, more than 2 cm in diameter. 
Piece-meal resection was followed by snare tip soft coa-
gulation of the entire resection margin (soft coag effect 
4, 80 watts). Surveillance endoscopy, performed at 5-6 
and 18 m, included meticulous inspection of the scar 
with white light and narrow band imaging with biopsi-
es of the scar center and margin and of any suspicious 
area. Close to 400 patients with over 400 lesions were 
included. Endoscopic recurrence was observed in ~7% 
in the ablation arm versus ~21% in the control arm, and 
histologic recurrence in respectively ~5% versus ~23%. 
Endoscopic assessment had a sensitivity of ~92%, a spe-
cificity of ~97% and a negative predictive value of ~99% 
for correctly identifying recurrence at the post-resection 
scar. The value of ablation of the margins has now been 
confirmed in other studies. Even in studies evaluating the 
usefulness of cold snare resection, the advice is usually 
given to include a generous surrounding tissue margin to 
decrease the risk of local recurrence.
A remaining challenge for endoscopists is the detection 
of deep submucosal cancerous invasion in polypoid le-
sions. Up to now, T1 colorectal polyps with one or more 
risk factors for lymph node metastasis are considered en-
doscopically unresectable. Can narrow band imaging (NBI) 
be helpful in identifying deep malignant invasion? A large 
multicenter prospective Spanish study explored the us-
efulness of NBI in over 1,600 patients with well over 200 
polyps larger than 1 cm. Pointers for deep invasion were 
– brown/dark brown discoloration with/without whiter 
patches -areas of disrupted/missing vessels – amorphous/
absent surface pattern. Of the lesions 4.2% had features of 
deep invasion and 4.3% were considered endoscopically 
unresectable. The NBI – based prediction of deep malig-
nant infiltration had a sensitivity 58%, a specificity of 96% 
and a positive and negative predictive value of respecti-
vely 42% and 98%. Beyond a doubt such results are en-
couraging but there is still room for improvement. We live 
certainly in exciting times, now that experts are exploring 
removal of (well differentiated) rectal lesions extending up 
to the muscularis propria by dissecting the plane between 
the circular and longitudinal muscle. The endoscopic bo-
undaries keep moving.
Biliopancreatic endoscopy 
Prof Marco Bruno
Developments in endoscopic ultrasound (EUS), bilio-
pancreatic endoscopy and endoscopic complications 
were discussed. Microbial contamination of endoscopic 
equipment remains a major (unsolvable?) problem for 
the endoscopist. Over the past 17 y, 32 documented 
duodenoscope-related outbreaks with multi-drug resis-
tant microorganisms, involving over 400 patients and le-
ading to death in over 20 patients, have been reported. 
Endoscopic contamination and patient infection have 
also occurred without breaches in the re-processing 
procedures. Scope contamination after a procedure is 
~8-10 log10; manual cleaning leads to a reduction with 
~4-6 log10 and further automated high level disinfecti-
on to another ~4-6 log10 reduction. The total reduction 
amounts to ~8-12 log10 leading to a low margin of sa-
fety of ~0-2 log10. Sratches and shredding in bending 
sections and remaining adherent debris interfere with 
the cleaning/disinfection efficacy. These results were 
again confirmed in a nation-wide duodenoscope cul-
ture study, showing that 22% of the duodenoscopes 
were contaminated with one or more microorganisms 
with 20 or more colony forming units and that 39% of 
the ERCP centers had at least 1 contaminated duode-
noscope hanging in the dryer cabinet. Contamination 
was not confined to a specific duodenoscope type but 
appeared related to the complex scope design and the 
inability to sufficiently clean all its intricate surfaces. A 
recent American FDA safety communication reads: For 
high concern organisms, defined as organisms that are 
more often associated with disease, such as E. coli and 
Pseudomonas aeruginosa, updated culturing results 
appear to show that up to 5.4% of properly collected 
samples test positive. Combined with strict adheren-
ce to the duodenoscope manufacturer’s reprocessing 
instructions, the following supplemental measures may 
further help reduce the risk of infection transmission as-
sociated with the use of duodenoscopes:
• microbiological culturing;
• ethylene oxide sterilization;
• use of a liquid chemical sterilant processing system;
•  repeat high-level disinfection. Perhaps the last recom-
mendation is the most sensible and realistic or shall we 
be using only disposable (duodeno)endoscopes in the 
not-to-distant future?
In a previous large scale Dutch controlled trial, a minimaly-
ly invasive step-up approach was shown to be superior at 
a follow-up of 6 m, to primary open surgical necrosec-
tomy in patients with (infected) necrotizing pancreatitis. 
The endpoint (mortality/major complications) was res-
pectively 40% versus 69%. Recently, the late outcome 
after ~ 86 m was superior for the step-up approach with 
significantly less new-onset multi-organ failure/systemic 
complications, incisional hertnia and need for pancrea-
tic enzyme therapy. Lumen-apposing metal stents are 
increasingly being used in the drainage of pancreatic 
walled-off necrosis instead of plastic pig-tail stents. A re-
cent meta-analysis showed a comparable overall clinical 
success rate of 88% with both modalities. Also the diffe-
rence in pooled adverse event rates of respectively 11% 
versus 16% was not significant, leaving the choice to the 
endoscopist’s preference. The overall similar outcomes 
between expandable metal versus pig-tail plastic was 
28Central European Journal of Gastroenterology and Hepatology 
Volume 5, Issue 4 / December 2019
Összefoglaló közlemények / Reviews
again shown in a British study with comparable techni-
cal and clinical success (above 90%), stent duration of an 
average 55 d and recurrence rates of around 5-6%. What 
was different was the higher rate of bleeding, 15% versus 
3%, with about half the bleeding in the metal stent co-
hort related to the development of a pseudo-aneurysm, 
necessitating vascular embolization. Other publications 
have drawn attention to this dreadful aneurysmal comp-
lication, caused by excessive pressure trauma of vessels 
in the wall of the necrotic cavity by the expandable metal 
stents. Patients should be prewarned of such potential 
complications.
Quite revolutionary is the rapidly spreading experience 
with EUS-guided gastrointestinal connections mainly 
for palliation of malignant obstruction. In one such stu-
dy, EUS-guided choledocho-duodenostomy was carri-
ed out in 46 patients with inoperable malignant distal 
bile duct obstruction. Technical and clinical success was 
respectively 93% and 98%. Adverse events occurred in 
12% (stent food impaction, delayed bleeding and stent 
migration). Reaching the papilla for ERCP can be chal-
lenging, for example after gastric bypass surgery with 
Roux-en-Y anastomosis for therapy of morbid obesity. 
Reaching the papilla may be attempted with a balloon-
fitted endoscope. Alternatively, the gastric pouch may 
be reconnected transmurally under EUS guidance. In a 
multicenter study, EUS-guided gastrogastrostomy was 
compared with endoscopy in 60 patients. Technical suc-
cess by reaching the papilla was seen in 100% versus 
60% with a procedure duration of 50 min versus 91 min, 
both in favor of the EUS-guided approach. Adverse ef-
fects were comparable with 10% and 7%. Several com-
parable studies, evaluating the efficacy of the EUS-gu-
ided transintestinal approach have been published, all 
indicating comparable technical and clinical success ra-
tes and comparable and sometimes even lower comp-
lication rates when compared to other modalities, such 
as percuteous transhepatic approches etc.
Also intriguing is the exploration of the usefulness of 
cholangioscopy now that the digital single-operator cho-
langioscope has become available. This technology was 
evaluated in a multicenter study with over 400 patients 
with difficult biliary stones, defined as
•  >15 mm,
•  >3,
•  intrahepatic/cystic duct, and/or – impacted or – associa-
ted with anatomic duct abnormality.
Complete bile duct clearance, either with electrohydrolic 
or laser lithotripsy was obtained in 97%, in 1 session in 
77%. ERCP’s for additional therapy such as stent removal 
or stricture treatment was necessary in 34%. The most 
important factor associated with technical failure was 
difficult anatomy or difficult cannulation. More than one 
session was more often necessary in patients with prior 
failed ERCP or in case of a prolonged initial cholangiosco-
py session. Current guidelines suggest cholangioscopy-
guided lithotripsy as an adjunct with or without balloon 
dilation or mechanical lithotipsy. Novel is the evaluation 
of direct cholangioscopy guided laser lithotripsy. Endos-
copic stone clearance was obtained in respectively 93% 
and 67% of the 60 patients. Dilation of the papilla was 
more often carried out in the conventional group and 
the procedure duration was substantially longer in the 
cholangioscopy group. The conventional approach was 
less successful in patients with prior ERCP attempt. The 
usefulness of cholangioscopy was also demonstrated for 
biopsy targeting of suspicious lesions, yet distinguishing 
between benign and malignant bile duct stricturing le-
sions often remains challenging. Whole exome and 
genome sequencing studies have defined the genetic 
landscape of neoplasms arising or secondarily involving 
the bile duct system. A 28-gene next-generation-sequen-
cing panel (BiliSeq) was prospectively evaluated in 346 
ERCP-obtained biliary specimens from 252 patients with 
bile duct strictures. The sensitivity and specificity of Bi-
liSeq for malignant strictures was respectively 73% and 
100%. In comparison, the sensitivity of elevated serum 
CA 19-9 was 76% and of pathological evaluation 48%. 
The combination of BiliSeq and pathological evaluation 
increased the sensitivity to 83% and maintained a spe-
cificity of 99%. BiliSeq improved the pathological sen-
sitivity for both biliary brushings and biopsies. Among 
patients with primary sclerosing cholangitis, BiliSeq had 
a sensitivity of 83% compared to 8% or pathological exa-
mination. Interestingly, in 8% the genomic alterations 
were useful in guiding therapy such as trastuzumab-ba-
sed treatment for ERBB2-amplified cholangiocarcinoma. 
Beyond doubt, increasingly molecular-based investiga-
tions will be incorporated in diagnostic/therapeutic en-
doscopy.
The explosive interest in pancreatic cysts has continued 
during the past year.The overall subtyping of cystic lesion 
is illustrated below (Fig. 14).
Fine needle aspiration cytology was the standard techno-
logy when trying to characterize the nature of the cystic 
lesion but attention is increasingly switching to the use 
of newly designed catheter-guided biopsy needles. No-
Figure 14. Pancreatic Cysts. What are we 
looking for? (14)
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vel is the development of catheter-guided microbiopsy 
forceps for targeted biopsy of the cystic wall. In 28 pati-
ents the micro-biopsy procedure was technically succes-
sful in 86%. Biopsies were generally of good quality and 
contributed to the diagnosis in over 70%. Adverse events 
occurred in 11%, usually mild pancreatitis. Such results 
were confirmed in another cohort of 56 patients where 
the procedure was technically successful in all. Mild ad-
verse events were seen in 16%, most commonly intra-
cystic bleeding. Specimens were considered adequate 
for histology in 84%, leading to an overall diagnostic ac-
curacy, combining histology and cytology of 84%. What 
the proper and cost-effective indications will be for use 
of micro-biopsy forceps equipment needs further larger 
scale detailed multicenter evaluation.
These narrative highlights cover only part of the lectures 
presented at the Gastro Update Europe 2019 meeting in 
Budapest. Not covered in this review are hepatology, on-
cology, neuromotility, surgery and the exciting case pre-
sentations. These highlights intend to illustrate the high 
educational level of the meeting, emphasizing the most 
important developments in gastroenterology – hepato-
logy of relevance for the practicing specialist. This type of 
compact and comprehensive update can be recommen-
ded for both fellows and astute practitioners in our discip-
line.
The Gastro Update Europe 2020 will be held on June 5 – 6, 
2019 in Bratislave, Slovakia (Vienna Airport). For more infor-
mation visit www.gastro-update-europe.eu
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